Regeneron entered radiopharmaceuticals through a collaboration with Telix Pharmaceuticals, targeting next-generation radiopharmaceutical therapies and diagnostics across solid tumors. Under the agreement, the companies plan to codevelop and co-commercialize multiple programs using a 50/50 cost- and profit-sharing model. Telix will receive an AU$57 million upfront payment for an initial set of four programs drawn from Regeneron’s antibody portfolio, with an option to extend to additional programs. The deal gives Regeneron new platform access in a market where theranostics and imaging-driven oncology strategies have increasingly shaped investment and product development. For Telix, the tie-up expands the commercial and development runway across targets, supporting a broader portfolio strategy beyond its existing pipeline programs.